
    
      A Phase I/II, Randomized, Placebo-Controlled Study of the Safety and Efficacy of
      Transendocardial Injection of Autologous Human Cells (Mesenchymal or the combination of MSC
      and Cardiac Stem Cells) in Patients With Chronic Ischemic Left Ventricular Dysfunction and
      Heart Failure Secondary to Myocardial Infarction.

      A total of 55 subjects participating, with 5 in the pilot phase and 50 in the randomized
      phase.

      Patients with chronic ischemic left ventricular dysfunction and heart failure secondary to MI
      scheduled to undergo cardiac catheterization.
    
  